State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 8,827,707 shares of Novavax Inc. common stock, representing 5.4 percent of the class, based on a triggering event dated September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 8,827,707 shares of Novavax common stock (CUSIP 670002401).
  • Percent of class: The 8,827,707 shares represent 5.4% of Novavax's outstanding common stock, according to the filing.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote for 8,362,217 shares, with zero sole voting power.
  • Shared dispositive power: The filing reports shared power to dispose of 8,827,707 shares and zero sole dispositive power.
  • Filing entity type: State Street Corporation identified itself as a parent holding company (type "HC"), organized in Massachusetts, with a principal office at One Congress Street, Suite 1, Boston, MA 02114.
  • Subsidiaries involved: Six State Street Global Advisors subsidiaries are identified as the entities that acquired the reported securities, each classified as an investment adviser (IA).

State Street's Disclosed Position in Novavax and How It Is Held

State Street Corporation, the Boston-based parent holding company, submitted a Schedule 13G disclosing a 5.4 percent beneficial ownership position in Novavax Inc., the vaccine developer headquartered at 700 Quince Orchard Road, Gaithersburg, Maryland 20878. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026, and carries a triggering event date of September 30, 2026. Novavax focuses on developing and commercializing protein-based vaccines, most notably its COVID-19 vaccine product, and is listed on a national exchange under the ticker symbol that corresponds to CUSIP 670002401.

All 8,827,707 shares are held through six investment adviser subsidiaries identified in the filing: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Singapore Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing carries the certification required under Schedule 13G that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." State Street reported zero sole voting power and zero sole dispositive power, with all voting and dispositive authority held on a shared basis across its subsidiary network.

The 465,490-share gap between the shared voting figure (8,362,217) and the shared dispositive figure (8,827,707) indicates that a portion of the beneficially owned shares are subject to dispositive authority but are not currently subject to shared voting power, a common feature of positions held in certain fund structures managed by registered investment advisers.

What Was Disclosed

State Street Corporation filed a Schedule 13G reporting a 5.4 percent beneficial ownership stake in Novavax Inc. common stock, amounting to 8,827,707 shares held on a shared basis through six State Street Global Advisors investment adviser subsidiaries, with the position measured as of September 30, 2026.